City University of New York (CUNY)

CUNY Academic Works
Publications and Research

College of Staten Island

2016

TriCurin, a novel formulation of curcumin, epicatechin gallate, and
resveratrol, inhibits the tumorigenicity of human
papillomaviruspositive head and neck squamous cell carcinoma
Longzhu Piao
Ohio State University

Sumit Mukherjee
CUNY College of Staten Island

Qing Chang
CUNY College of Staten Island

Xiujie Xie
Ohio State University

Hong Li
Ohio State University

See next page for additional authors

How does access to this work benefit you? Let us know!
More information about this work at: https://academicworks.cuny.edu/si_pubs/147
Discover additional works at: https://academicworks.cuny.edu
This work is made publicly available by the City University of New York (CUNY).
Contact: AcademicWorks@cuny.edu

Authors
Longzhu Piao, Sumit Mukherjee, Qing Chang, Xiujie Xie, Hong Li, Mario R. Castellanos, Probal Banerjee,
Hassan Iqbal, Ryan Ivancic, Xueqian Wang, Theodoros N. Teknos, and Quintin Pan

This article is available at CUNY Academic Works: https://academicworks.cuny.edu/si_pubs/147

www.impactjournals.com/oncotarget/

Oncotarget, 2017, Vol. 8, (No. 36), pp: 60025-60035
Research Paper

TriCurin, a novel formulation of curcumin, epicatechin gallate, and
resveratrol, inhibits the tumorigenicity of human papillomaviruspositive head and neck squamous cell carcinoma
Longzhu Piao1,2, Sumit Mukherjee3,4, Qing Chang4,5, Xiujie Xie1,2, Hong Li6, Mario
R. Castellanos7, Probal Banerjee3,4, Hassan Iqbal1,2, Ryan Ivancic1,2, Xueqian
Wang1,2, Theodoros N. Teknos1,2 and Quintin Pan1,2
1

Department of Otolaryngology-Head and Neck Surgery, The Ohio State University Medical Center, Columbus, Ohio, USA

2

Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University Comprehensive Cancer
Center, Columbus, Ohio, USA

3

Ph.D. Program in Biochemistry at the Graduate Center of the City University of New York, New York, USA

4

Department of Chemistry and Center for Developmental Neuroscience, College of Staten Island, Staten Island, New York, USA

5

Department of Pathology and Laboratory Medicine, Staten Island University Hospital, Northwell Health, Staten Island, New
York, USA

6

Division of Pharmaceutics, College of Pharmacy, The Ohio State University, Columbus, Ohio, USA

7

Division of Research, Department of Medicine, Staten Island University Hospital, Northwell Health, Staten Island, New York, USA

Correspondence to: Quintin Pan, email: Quintin.Pan@osumc.edu
Keywords: human papillomavirus, p53, head and neck cancer, curcumin, catechin
Received: December 22, 2015     Accepted: May 13, 2016     Published: July 16, 2016
Copyright: Piao et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY
3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

ABSTRACT
Head and neck squamous cell carcinoma (HNSCC) is the sixth most prevalent
cancer worldwide with about 600,000 new cases diagnosed in the last year. The
incidence of human papillomavirus-positive head and neck squamous cell carcinoma
(HPV-positive HNSCC) has rapidly increased over the past 30 years prompting the
suggestion that an epidemic may be on the horizon. Therefore, there is a clinical
need to develop alternate therapeutic strategies to manage the growing number
of HPV-positive HNSCC patients. TriCurin is a composition of three food-derived
polyphenols in unique stoichiometric proportions consisting of curcumin from the
spice turmeric, resveratrol from red grapes, and epicatechin gallate from green
tea. Cell viability, clonogenic survival, and tumorsphere formation were inhibited
and significant apoptosis was induced by TriCurin in UMSCC47 and UPCI:SCC090
HPV-positive HNSCC cells. Moreover, TriCurin decreased HPV16E6 and HPV16E7 and
increased p53 levels. In a pre-clinical animal model of HPV-positive HNSCC, intratumoral injection of TriCurin significantly inhibited tumor growth by 85.5% compared
to vehicle group (P < 0.05, n = 7). Our results demonstrate that TriCurin is a potent
anti-tumor agent for HPV-positive HNSCC. Further development of TriCurin as a novel
anti-cancer therapeutic to manage the HPV-positive HNSCC population is warranted.

INTRODUCTION

recently, high-risk human papillomavirus (HPV) infection,
in particular HPV16, has emerged as an etiologic factor
for the development of HNSCC [3]. Overall, about 25%
of all HNSCC are positive for HPV DNA. HPV-positive
HNSCC displays clinical and molecular features that
distinguish it from the traditional alcohol- and smokingrelated HPV-negative HNSCC [4]. Retrospective and

Approximately 600,000 new cases of head and
neck squamous cell carcinoma (HNSCC) are diagnosed
worldwide each year [1, 2]. These cancers are strongly
associated with certain environmental and lifestyle risk
factors, such as tobacco and alcohol consumption. More
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prospective studies have shown that HPV-positive
HNSCC patients have better response rates and clinical
outcomes than HPV-negative HNSCC patients [5].
Standard of care treatment paradigms consisting of
chemotherapy and/or radiation for HNSCC are fairly toxic
and associated with high morbidity and quality of life
issues. Based on these concerns, there were discussions
and now clinical trials designed to assess the impact of
treatment de-intensification strategies for the HPV-positive
HNSCC population. Alternatively, novel less-toxic
therapeutic approaches need to be developed to add to the
armamentarium to manage HPV-positive HNSCC patients.
Several pre-clinical studies reported that natural
phenolic compounds have anti-HPV and anti-cancer
activity [6, 7]. Plant phenols play an important role in
cancer prevention. Epidemiologic studies show diets
high in these polyphenol-rich foods, such as vegetables
and fruits, are associated with reduced cancer rates [8].
Curcumin is a polyphenol extracted from the food spice
turmeric. In China and India, turmeric has been used as
medicinal herb to treat various ailments over the centuries.
Numerous scientific reports have shown that curcumin
has anti-cancer activity and targets numerous oncogenic
pathways [9–12]. Our group demonstrated that curcumin
eliminates various HPV-positive cervical carcinoma cell
lines and is non-toxic to healthy tissue [13]. Resveratrol
is a polyphenol found in grapes, it is also a potent
antioxidant [14–17] with anti-inflammatory and cancerpreventive [18–21] properties. Studies reported that both
curcumin and resveratrol displayed synergistic effects with
cancer therapeutics [22–24]. Epicatechin gallate is one of
the major catechins in green tea and also has shown anticancer activity on a variety of cell types [25]. Although
pre-clinical studies show these polyphenols as promising
anti-cancer compounds, clinical trials evaluating
curcumin, epicatechins, and resveratrol have had only
marginal results due to poor bioavailability and low target
tissue uptake [26, 27].
To overcome the clinical challenge associated with
developing polyphenols as a therapeutic, TriCurin, a triple
polyphenol combination consisting of curcumin, epicatechin
gallate, and resveratrol in specific stoichiometric proportions,
was formulated to maximize anti-tumor activity. In this
study, TriCurin was highly active to eliminate HPV-positive
HNSCC cells in vitro and in vivo. Our work provides initial
evidence that TriCurin may be a promising therapeutic to
manage HPV-positive HNSCC patients.

was calculated to be 3.22 µM+ and 1.86 µM+ for
UMSCC47 and UPCI:SCC090, respectively. TriCurin
(3 µM+ for 72 hours) promoted apoptosis in both
HPV16-positive HNSCC cell lines (Figure 1B). In
comparison with vehicle, TriCurin induced 66.1
± 3.6% apoptosis in UMSCC47 (P < 0.01, n = 3),
and 11.8 ± 0.7% apoptosis in UPCI:SCC090 cells
(P < 0.01, n = 3). Clonogenic survival assay was used
to assess the clonal proliferation of surviving cells
over a prolonged time-period. As shown in Figure 1C,
clonogenic survival of UMSCC47 and UPCI:SCC090
cells was compromised with TriCurin treatment (3
µM+ for 24 hours); 66.7 ± 3.0% (P < 0.01, n = 3)
inhibition for UMSCC47 and 92.4 ± 1.0% inhibition
for UPCI:SCC090 (P < 0.01, n = 3). Moreover, the
combination of TriCurin and radiation was more
active (P < 0.01, n = 3) than either single intervention
to ablate UMSCC47 cells (Supplementary Figure
1). Radiation (3 Gy) reduced clonogenic survival of
UMSCC47 cells by 44.8 ± 1.7% whereas the TriCurin
and radiation combination decreased the number of
survival clones by 79.9 ± 3.6%. The ability of cells to
form spheres under non-adherent culture conditions has
been widely used as an in vitro assay to assess normal
stem cells and cancer initiating cells (CICs). Our group
showed that tumorspheres are enriched for CICs and a
single tumorsphere has the potential to generate a bulky
tumor in vivo [28]. Tumorsphere formation efficiency
was reduced in a dose-dependent manner with TriCurin
treatment (Figure 1D). At the highest concentration
(10 µM+), TriCurin decreased tumorsphere formation
efficiency by 66.1 ± 7.8% (P < 0.01, n = 3) in
UMSCC47 and 56.7 ± 4.7% (P < 0.01, n = 3)
in UPCI:SCC090. In addition, TriCurin reduced
tumorsphere diameter by 16.0 ± 0.8% (P < 0.05, n = 3)
in UMSCC47 and 19.4 ± 0.3% (P < 0.05, n = 3) in
UPCI:SCC090 (Figure 1E).

TriCurin reduces HPV16E6/E7 and enhances
p53/Rb levels in HPV-positive HNSCC
It is well recognized that HPV16 oncogenes,
E6 and E7, inactivates p53 and Rb, respectively, to
drive HPV- induced carcinogenesis. shRNA-mediated
knockdown of HPV16E6/E7 is sufficient to promote
apoptosis and ablate HPV16-positive HNSCC cells
[29]. Therefore, we determined if the global anti-tumor
effect of TriCurin is mediated through suppression
of HPV16E6/E7. In Figure 2, TriCurin treatment
dramatically reduced HPV16E6 and HPV16E7 mRNA
expression and protein levels in UMSCC47 and
UPCI:SCC090 cells. Moreover, an increase in p53 and
Rb levels were observed following TriCurin treatment.
These results confirm that TriCurin targets HPV16E6/
E7 resulting in an accumulation of p53 and Rb in HPVpositive UMSCC47 and UPCI:SCC090 cells.

RESULTS
TriCurin promotes a global anti-tumor response
in HPV-positive HNSCC
Two HPV16-positive HNSCC cell lines, UMSCC47
and UPCI:SCC090, were tested for growth inhibition
using a dose range of TriCurin (Figure 1A). The IC50
www.impactjournals.com/oncotarget
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TriCurin retards tumor growth in vivo

with established tumors were randomly assigned to
two treatment arms; vehicle or TriCurin (3×/week for
5 weeks). Intra-tumor therapy for the treatment of HNSCC
has been previously proposed using gene therapy [30].
Though only limited effects have been seen in these phase 1
and 2 clinical trials [31], the feasibility of doing intra-tumor
treatment was validated in the clinical setting. Intra-tumoral

The in vivo activity of TriCurin was assessed in a
pre-clinical mouse model of HPV16-positive HNSCC.
UMSCC47 cells were implanted into the flanks of
athymic nude mice and allowed to establish without
treatment. At 41 days post-tumor cell implantation, mice

Figure 1: TriCurin promotes a global anti-tumor response in HPV-positive HNSCC. (A) IC50. The MTS reagent was used

to measure cell proliferation. Dose response curve and IC50 of TriCurin were generated using GraphPad Prism software. (B) Apoptosis.
UMSCC47 and UPCI:SCC090 cells were treated with control or TriCurin (3 µM+). Cells were stained with FITC-Annexin V and propidium
iodide and analyzed by flow cytometry. Data are presented as mean ± SEM. *P < 0.01, n = 3. (C) Clonogenic survival. UMSCC47 and
UPCI:SCC090 cells were treated with control or TriCurin (3 µM+). The number of surviving clones was assessed by counting the number
of clones under a microscope after crystal violet staining. A representative well for each experimental condition is shown and data are
presented as mean ± SEM. *P < 0.01, n = 3. (D) Tumorsphere formation efficiency and diameter. UMSCC47 and UPCI:SCC090 cells
were treated with control or TriCurin (1, 3, or 10 µM+) and cultured in ultralow attachment plates. Tumorsphere formation efficiency was
calculated as the number of tumorspheres formed divided by the original number of cells seeded. Tumorsphere diameter was measured
using NIS-Elements software. Data are presented as mean ± SEM. *P < 0.01, n = 3 for tumorsphere formation efficiency. *P < 0.05, n = 3
for tumorsphere diameter.
www.impactjournals.com/oncotarget
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vehicle-treated tumors also had regions of necrosis but
comparatively much less necrotic tissue than the TriCurintreated tumors. Ki67 immunohistochemical staining
showed that TriCurin treatment reduced the number of
actively proliferating tumor cells by 19.9% (P < 0.003)
compared to vehicle (Figure 3E). Furthermore, TriCurin
dramatically reduced the intra-tumoral levels of HPV16E6
(94.9% inhibition, P < 0.001) (Figure 4).

delivery of TriCurin inhibited tumor growth by 85.5% (P
< 0.05, n = 7) (Figure 3A). At the end of the treatment
protocol, mice were sacrificed and tumors were resected
and weighed. TriCurin reduced the tumor weight by 86.3%
(P < 0.01, n = 7); the mean tumor weight was 904.3 ±
203 and 123.5 ± 42.8 mgs for the vehicle and TriCurin,
respectively (Figure 3B). Analysis of the H&E stained
tumor sections from the TriCurin group showed that the
majority of the tumor consisted of large necrotic areas
with small regions of tumor cells present in the tumor
periphery (Figure 3C). In contrast, as shown in Figure 3D,
the tumors from the vehicle group were multi-lobulated
and predominantly populated with tumor cells. The

DISCUSSION
HNSCC encompasses many site-specific cancers,
including oral cavity and oropharyngeal cancers. Alcohol

Figure 2: TriCurin reduces HPV16E6/E7 and enhances p53/Rb levels in HPV-positive HNSCC. UMSCC47 and

UPCI:SCC090 cells were treated with control or TriCurin (3 µM+ for 72 hours. (A) HPV16E6/E7 and p53/Rb mRNA expression. mRNA
expression was determined by qRT-PCR. Data were normalized to GAPDH and presented as mean ± SEM. *P < 0.001, n = 5. (B) HPV16E6/
E7 and p53/Rb protein levels. Protein levels were determined by immunoblot analyses.
www.impactjournals.com/oncotarget

60028

Oncotarget

and tobacco are the traditional risk factors for HNSCC
and incidence rates are found to be higher in regions
with high rates of alcohol and tobacco consumption
[32]. During the past few decades, several countries have
witnessed a decline in oral cavity cancer incidence due
to a decline in tobacco use. However, Canada, Denmark,
the Netherlands, Norway, Sweden, the United States,
and the United Kingdom, have seen an increasing rate of
oropharyngeal and oral cavity cancers despite declines in

smoking rates since the 1980s. The increase in HNSCC
incidence rate in these developed countries is attributed to
HPV, in particular high-risk HPV16 [33]. It is estimated
that by 2025, the number of new HPV-positive HSNCC
cases will be similar if not greater than the number of
new HPV-positive cervical cases. Thus, there is a critical
need to develop novel therapeutic strategies to better
manage the growing number of HPV-positive HNSCC
population.

Figure 3: TriCurin retards tumor growth in a pre-clinical model of HPV-positive HNSCC. (A) Tumor volume. UMSCC47

cells were implanted into the flanks of athymic nude mice and tumors were allowed to develop without treatment. At 41 days post-tumor
cell implantation, mice with palpable tumors were randomly assigned to two treatment arms: vehicle or TriCurin (3×/week for 5 weeks).
Tumors were measured using a digital caliper and tumor volumes were calculated. Data are presented as mean ± SEM. *P < 0.05, n = 7.
(B) Tumor weight. Mice were sacrificed at the end of the treatment protocol and tumors were resected and weighed. Data are presented
as mean ± SEM. *P < 0.01, n = 7. (C) H&E histopathology. A representative image from a tumor in the control or TriCurin-treated group
is shown. Tumors from TriCurin-treated mice showed large necrotic areas (yellow arrows) with residual tumor cells (green arrows) in the
periphery. Tumors from control-treated mice were multi-lobulated with large areas populated with residual tumor cells. (D) Ki67 staining.
Typical areas for each case were photographed with a 20× objective lens and shown. The Ki67 labeling index was scored as the percentage
of tumor cell nuclei showing definite nuclear immunoreactivity above the background level using Image J. Data are presented as mean ±
SEM. *P < 0.003.
www.impactjournals.com/oncotarget
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Figure 4: TriCurin reduces intra-tumoral levels of HPV16E6. Representative immunofluorescence images from a tumor in

the control or TriCurin-treated group are shown (scale bar: 300 µm). Nuclear staining with HOECHST33342 was used to normalize for
HPV16E6 staining intensity. Data are presented as mean ± SEM. *P < 0.001.
www.impactjournals.com/oncotarget
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Polyphenols are present in foods and beverages
of plant origin (fruits, vegetables, cereals, herbs, spices,
legumes, nuts, olives, chocolate, tea, coffee, and wine) and
are the most abundant antioxidants in the human diet [34].
Polyphenols show many beneficial effects on human health
including antimicrobial, anti-inflammatory, anti-viral, antitumoral, and immunomodulatory activities [35–39]. One
of the most potent and promising anti-tumor polyphenols
reported in preclinical studies is curcumin [10, 11].
Curcumin has been shown to promote apoptosis through
PARP-dependent and PARP-independent pathways.
Recent work revealed a role for apoptosis inducing factor
in curcumin-mediated apoptosis [40]. These results
demonstrate that curcumin-mediated cell death is complex
and may involve multiple apoptotic pathways. Our group
demonstrated that curcumin effectively eliminates various
HPV-positive cervical carcinoma cell lines in vitro; prior
to cell death, curcumin simultaneously decreased HPVE6
levels and induced the expression of p53 [13]. The antitumor effect of curcumin was not HPV-type specific,
showing activity against high-risk HPV genotypes 16,
18, and 68. Similarly, the polyphenols extracted from
green tea, catechins, have shown potent activity against
HPV-positive carcinoma cells. Catechins inhibit cell
proliferation in a dose-dependent manner and directly
inhibit HPVE6 and HPVE7 [41]. Resveratrol is another
polyphenol with anti-tumor activity and promotes cell
cycle arrest and apoptosis in HPV-positive cervical
carcinoma cells [7]. These plant-derived polyphenols
demonstrated promising pre-clinical efficacy; however,
curcumin, catechins, and resveratrol have not advanced
beyond clinical trials due to limitations, such as rapid
metabolism and low target tissue bioavailability.
Our previous work demonstrated that single-agent
curcumin, epicatechin gallate, or resveratrol inhibits
proliferation and E6 levels in HPV-positive HeLa cervical
carcinoma [42, 43]. Combination therapy of curcumin,
epicathechin gallate, and resveratrol at their IC50 doses
(16 µM, 16 µM, and 65 µM, respectively) showed general
toxicity and did not discriminate between HeLa cells
and normal fibroblasts [42]. Comprehensive single-,
double-, and triple-agent studies revealed that curcumin,
epicatechin gallate, and resveratrol at a defined molar
ratio of 4:1:12.5 (TriCurin) was selective to ablate HeLa
cells and furthermore, more active than each individual
component or the doublet of curcumin and epicatechin
gallate or curcumin and resveratrol [42]. Moreover,
intra-lesional administration of TriCurin was highly
active and inhibited in vivo tumor growth of HPV16E6/
E7, c-Ha-ras-expressing TC-1 cells by 80% [42]. In the
present study, TriCurin exhibited high anti-tumor activity
in vitro and in vivo against HPV16-positive HNSCC
cells. HPV16E6 and HPV16E7 levels were dramatically
reduced, whereas, p53 and Rb levels were increased
with TriCurin treatment. Since HPV16E6 and HPV16E7
oncogenic proteins are essential for cell transformation
www.impactjournals.com/oncotarget

and tumor cell maintenance, we suggest that a potential
mechanism of action of TriCurin in HPV16-positive
HNSCC cells is through reduction of the HPV16E6/E7
viral proteins. Our in vivo data show that intra-tumor
delivery of TriCurin results in a large amount of tumor
cell death in the region of the injection site. Furthermore,
tumor cells in the periphery of the tumor showed an altered
phenotype with decrease Ki67 staining and a significant
decrease in the levels of the viral oncogenic HPV16E6
protein. Radiation is a standard of care for HNSCC
patients and the observation that TriCurin potentiates the
anti-tumor efficacy of radiation provides initial evidence
that the TriCurin and radiation combination should be
extensively explored in future studies. Taken together, our
findings provide initial evidence that TriCurin may be an
alternative therapeutic approach to manage HPV-positive
HNSCC.

MATERIALS AND METHODS
TriCurin
Detailed description of the development of TriCurin
has been described [42]. Briefly, curcumin, epicatechin
gallate, and resveratrol at the molar proportion 4:1:12.5
were prepared at various doses. A solution of 1.28 mM+
TriCurin (1.28 mM curcumin:0.32 mM epicatechin
gallate:4 mM resveratrol) in PBS plus 0.1% DMSO
was prepared by dilution from solutions of curcumin
and resveratrol in DMSO and a solution of epicatechin
gallate in PBS. Subsequently, 64 µM+, 32 µM+, 16 µM+,
8 µM+, 4 µM+, 2 µM+ and 1 µM+ TriCurin solutions
were prepared through serial dilutions of the 1.28 mM+
in PBS. For the treatment of cells to determine IC50,
TriCurin was diluted in the corresponding culture medium.

Cell culture
UMSCC47 and UPCI:SCC090 HPV16-positive
HNSCC cells were obtained from Dr. Thomas Carey
(University of Michigan) and Dr. Susanne Gollin
(University of Pittsburgh), respectively. Cells were
maintained at 37°C, 5% CO2 and 95% humidity in
Dulbecco’s modified Eagle’s medium containing 10%
(v/v) fetal bovine serum (BioWhittaker, Walkersville,
Maryland, USA), 100 units/ml penicillin and 1000 µg/ml
streptomycin (Invitrogen, Carlsbad, California, USA).
Cell lines were authenticated using short tandem repeat
profiling every six months by our research group.

MTS assay
The sensitivity of cells to TriCurin was measured
using the MTT-based colorimetric cell proliferation kit
(Roche Applied Science, Mannheim, Germany). Briefly,
3000 cells/well were plated in a 96 well plate. The next
60031
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day, cells were treated with different concentrations of
TriCurin. After 72 hours, 10 µL/well of MTT solution
was added to each well and further incubated for 4 hours
at 37°C. The formazan crystals formed in the wells
were solubilized by adding solubilization solution and
incubating the plates for 4 hr at 37°C. The plates were read
at 490 nm on a Spectramax 190 plate reader (Molecular
Devices Inc., Sunnyvale, CA). The percentage cell growth
inhibition for each treatment group was calculated by
adjusting the untreated control group to 100%. Data were
analyzed using GraphPad Prism software (GraphPad
Software, Inc., San Diego, CA) and the dose response
curves were used to calculate the concentration of TriCurin
resulting in 50% inhibition of cell proliferation (IC50)
using a four parametric logistical model. All experiments
were repeated at least 3 times.

consisted of an initial denaturation step at 95°C for
10 minutes, followed by 40 cycles of PCR at 95°C for
15 seconds, 60°C for 60 seconds. Standard curves were
generated and the relative amount of p53, HPV16E6, and
HPV16E7 was normalized to GAPDH, respectively.

Western blot analysis
Whole cell lysates were mixed with Laemmli
loading buffer, boiled, separated by sodium dodecyl
sulfate polyacrylamide gel electrophoresis, and transferred
to a PVDF membrane. Subsequently, immunoblot
analyses were performed using antibodies specific to
p53 (Calbiochem, San Diego, CA), HPV16E6 (Abcam,
Cambridge, MA), HPV16E7 (Cervimax, Vienna, Austria),
or GADPH (Cell Signaling Technology, Danvers, MA).
The signal was developed with ECL (Thermo Fisher
Scientific) after incubation with appropriate secondary
antibodies.

Apoptosis analysis
Cells were plated in 6-well plate and incubated
with vehicle or TriCurin (3 µM) for 72 hours. Cells were
stained with FITC-Annexin V and propidium iodide (Life
Technologies, OR, USA) and analyzed by flow cytometry.

Pre-clinical model of HPV-positive HNSCC
Athymic nude (NCr) mice were purchased from
Charles River Laboratories (Wilmington, MA) and housed
at The Ohio State University animal facility. Animals were
allowed to acclimate for 1 week prior to experimentation.
All animal work performed was in accordance with
and approved by the Institutional Animal Care and Use
Committee at The Ohio State University. UMSCC47 cells
grown to 80% confluence were harvested, and the cells
(1 × 106) mixed with Matrigel (1:1) were implanted into
the flanks of 8-week old female athymic nude mice and
tumors were allowed to develop without treatment. At
41 days after implantation, mice with palpable tumors
were assigned to two experimental groups and treated
with 0.1% DMSO in PBS-control or 1.28 µM+ TriCurin (5
µL, three times per weekly, n = 7) by direct intra-tumoral
injection. Tumors were measured using a digital caliper
and tumor volumes were calculated using the formula:
tumor volume = length × width × height × 0.5.

Clonogenic survival assay
Cells were incubated with vehicle or TriCurin for
24 hours (3 µM), harvested and collected, then suspended
in complete growth medium. Cells were seeded onto
6-well plates and allowed to grow until visible colonies
formed (7–10 days). The cell colonies were fixed with
cold methanol, stained with 0.25% crystal violet in 25%
methanol, washed and air-dried.

Tumorsphere formation assay
Cells were incubated with vehicle TriCurin for 24
hours (1, 3, 10 µM), harvested, and collected and washed
to remove serum, then suspended in serum free DMEM/
F12 supplemented with 1% antibiotic-antimycotic (Life
Technologies, OR, USA), 20 ng/mL human recombinant
epidermal growth factor (hrEGF), 10 ng/mL human
recombinant basic fibroblast growth factor (hrbFGF), 2%
B27 supplement (Invitrogen, Carlsbad, CA, USA), 1% N2
supplement (Invitrogen, Carlsbad, CA, USA). Subsequently,
cells were cultured in ultralow attachment 96-well plates
(Corning Inc., Corning, NY, USA) for tumorsphere formation.

Immunohistochemistry
After the treatment protocol, the mice in both
experimental groups were sacrificed and the entire
tumors were resected. About two-thirds of each tumor
was fixed in 4% paraformaldehyde. The formalin-fixed,
paraffin-embedded tissues were sectioned at 4 microns
and stained with hematoxylin and eosin (H&E) for
histologic examination. Immunohistochemistry for Ki67
levels was performed using an antibody against the
C-terminal portion of Ki67 (Catalog # 790-2910, Ventana
Medical Systems Inc., Tucson, AZ). Immunostaining was
performed on an autoimmunostainer (Ventana XT System
Benchmark; Ventana Medical Systems) according to the
manufacturer’s recommendations. Ki67 immunostaining

Quantitative real-time reverse transcription PCR
Real-time reverse transcription PCR was performed
using real-time PCR universal reagent and ABI-7900HT
real-time PCR machine (Applied Biosystems). All
reactions were done in a 20 µl reaction volume in triplicate
using validated TaqMan Gene Expression Assays for p53,
HPV16E6, HPV16E7, and GAPDH. PCR amplification
www.impactjournals.com/oncotarget
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was evaluated by two pathologists. The typical areas
for each case were photographed with a 20× objective
lens using a Nikon microscope and digital camera DSL3 (Nikon, Tokyo, Japan). The Ki67 labeling index was
scored as the percentage of tumor cell nuclei showing
definite nuclear immunoreactivity above the background
level using Image J (National Institute of Health).
About a third of each excised tumor was processed for
immunofluorescence staining for HPV16/18E6. Coronal
sections (30 µm) were made from 4% paraformaldehydefixed and 30% sucrose-soaked tumors. Tumor sections of
three animals from each group were processed as follows
for antigen retrieval: incubation with formamide 2 × SSC
(1:1), 55°C for 2 h, and then 5 min in 2 × SSC (NaCl
and sodium citrate) at room temperature. After blocking
overnight at 4°C in 0.1 % Triton X-100, 3% goat serum
in 100 mM phosphate buffered saline (PBS), the sections
were treated overnight with primary antibody: HPV16/18
E6 (C1P5; sc-460) (1:100), (diluted in 2% goat serum and
0.1% Triton X-100 in PBS). Secondary antibody control
sections were incubated overnight at 4°C in blocking
solution. After washing three times with PBS, the goat
anti-mouse-488 secondary antibody (Invitrogen-Molecular
Probes) (1:1000 dilution) was added to the primary
antibody-treated as well as secondary control sections.
Following overnight incubation at 4°C and three washes
with PBS, the sections were treated with HOECHST33342
(10 µg/ml) for 30 min at room temperature. Next, the
sections were washed three times with PBS and mounted
on microscope slides with Gold anti-fade mounting fluid
(Invitrogen-Molecular Probes). Confocal imaging was
conducted using a Leica SP2 microscope. ImageJ was
used to obtain the HPV16/18E6 and HOECHST33342
fluorescence intensity. HPV16/18E6 intensity (green) was
normalized to HOECHST33342 intensity (blue).

No conflicts of interest to disclose.
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